Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health Corporation filings document formal disclosures for a NYSE-listed health care company with retail pharmacy, pharmacy benefit management, health insurance, clinic, specialty pharmacy, and consumer wellness operations. Recent Form 8-K reports furnish quarterly and annual operating results, financial guidance, investor-day materials, and material events tied to business performance.
The company's proxy materials and other filings describe board composition, director independence, committee assignments, executive compensation, stockholder voting matters, and governance practices. Additional 8-K disclosures record board leadership changes, common-stock registration information, and Omnicare subsidiary chapter 11 proceedings and related financing disclosures.
AGUIRRE FERNANDO reported acquisition or exercise transactions in this Form 4 filing.
CVS Health Corp director Fernando Aguirre received a stock grant as part of his board compensation. On May 14, he was awarded 1,563 shares of CVS common stock at a reference price of $97.15 per share, issued in payment of a semi-annual retainer under the 2017 Incentive Compensation Plan. Following this award, he directly holds 42,513 CVS shares. This was a compensation-related grant, not an open-market purchase.
Balser Jeffrey R. reported acquisition or exercise transactions in this Form 4 filing.
CVS Health Corp director Jeffrey R. Balser received a grant of 2,058 shares of common stock on May 14, 2026 at $97.15 per share. According to the footnote, the stock was issued as payment of a semi-annual retainer under the 2017 Incentive Compensation Plan. After this award, he directly owns 15,717 CVS shares.
KIRBY J SCOTT reported acquisition or exercise transactions in this Form 4 filing.
CVS Health director J. Scott Kirby received 1,447 shares of Common Stock as a grant on May 14, 2026. The shares were issued at a stated market price of $97.15 per share as payment of a semi-annual retainer under the 2017 Incentive Compensation Plan, bringing his direct holdings to 14,434 shares.
Norwalk Leslie V reported acquisition or exercise transactions in this Form 4 filing.
CVS Health Corp director Leslie V. Norwalk received a grant of 1,447 shares of common stock on May 14, 2026. The shares were issued as payment of a semi-annual retainer at a market price of $97.15 per share under the company’s 2017 Incentive Compensation Plan. After this award, Norwalk directly holds 7,376 CVS common shares.
CVS Health Corp director Guy P. Sansone received a stock grant as part of his board compensation. He acquired 1,447 shares of common stock valued at $97.15 per share, issued in payment of a semi-annual retainer at the market price under the 2017 Incentive Compensation Plan. Following this grant, he directly holds 15,106.355 CVS shares.
CVS Health director Alecia A. Decoudreaux received a compensation-related grant of deferred stock units. On May 14, 2026, she was awarded 1,447.5039 deferred stock units valued at $97.15 per unit for deferring a semi-annual director retainer under CVS Health’s 2017 Incentive Compensation Plan. Each unit will later convert into one share of common stock, to be issued in the future according to her election. Following this grant, she directly holds a total of 42,181.8314 deferred stock units. The filing shows no open-market purchases or sales, only this grant/award acquisition.
CVS Health Corp director Anne A. Finucane reported receiving a grant of 1,544.0041 Deferred Stock Units as compensation. These units represent the deferral of a semi-annual director retainer, valued at a reference price of $97.15 per unit under CVS’s 2017 Incentive Compensation Plan.
Each deferred stock unit is designed to convert into one share of CVS common stock and be issued in the future, based on the director’s election. Following this award, Finucane holds a total of 18,355.0364 deferred stock units, reflecting her accumulated deferred board compensation.
BROWN C DAVID II reported acquisition or exercise transactions in this Form 4 filing.
CVS Health Corp director C. David Brown II received 1,544 shares of Common Stock as compensation. The shares were issued at a reference price of $97.15 per share as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, rather than bought on the open market.
After this grant, Brown directly holds 129,316 CVS shares. This is a routine equity award tied to board service and not an open-market purchase or sale.
CVS Health director Douglas H. Shulman received a grant of 1,447.5039 deferred stock units as compensation. The award represents deferral of a semi-annual director retainer under CVS Health’s 2017 Incentive Compensation Plan and is valued at $97.15 per unit. Each deferred stock unit is scheduled to convert into one share of CVS common stock and be issued in the future, according to the timing Mr. Shulman has elected. This is a compensation-related, non‑market transaction rather than an open‑market purchase or sale.
CVS Health Corp director Larry Robbins reported an acquisition of deferred stock units as part of non-employee director compensation. He received 1,930.0051 deferred stock units valued at $97.15 per unit, bringing his direct holdings of deferred stock units to 10,147.6418.
The award reflects a deferral of a semi-annual retainer under CVS Health’s 2017 Incentive Compensation Plan. Each deferred stock unit is designed to convert into one share of common stock, issuable when Robbins retires from the CVS Health Board of Directors, consistent with his deferral election.